KI-Beratung Beta

Gutscheinbedingungen

**Gültig bis 18.11.2026 auf englischsprachige Klassiker (klassiker-32728) online auf thalia.at und in der Thalia App. Einzelne Artikel können ausgeschlossen sein. Ausgenommen sind preisgebundene Artikel & eBooks. Pro Einkauf einmal einlösbar. Click & Collect nur bei Onlinevorabzahlung möglich. Keine Barauszahlung. Nicht kombinierbar mit anderen Aktionen und Gutscheinen. Gutschein wird auf max. 500€ Bestellwert angerechnet. Nicht gültig für Geschenkkarten, Versandkosten und Services.

Produktbild: Protein Serine/Threonine Kinases in Neurodegenerative Disorders

Protein Serine/Threonine Kinases in Neurodegenerative Disorders

191,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Protein Serine/Threonine Kinases in Neurodegenerative Disorders discusses protein kinase inhibitors and their potential role in modulating and treating neurodegenerative diseases. The book introduces protein kinases and inhibitors and includes detailed discussions on different types of kinases, including...

Beschreibung

Protein Serine/Threonine Kinases in Neurodegenerative Disorders discusses protein kinase inhibitors and their potential role in modulating and treating neurodegenerative diseases. The book introduces protein kinases and inhibitors and includes detailed discussions on different types of kinases, including protein kinase C (PKC), AMP-activated protein kinase (AMPK), death-associated protein kinase 1 (DAPK1), cyclin-dependent kinases (CDKs), glycogen synthase kinases (GSKs), Rho-associated protein kinase (ROCK), microtubule affinity regulating kinases (MARKs), mammalian target of rapamycin (mTOR), leucine-rich repeat kinase 2 (LRRK2), PTEN-induced kinase 1 (PINK1), and dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), and their roles in neurodegenerative disease, potential inhibitors, and therapeutic mechanisms.
This book features 23 chapters written by renowned experts in the field of kinases. It explores novel targets modulated by protein kinases, including noncoding RNAs (ncRNAs) and mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases, and their roles in neurodegeneration. It also discusses the nexus between glycogen synthase kinases (GSKs) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their role of metabolic regulation in neurodegeneration. The modulatory effects of protein kinase B (PKB/AKT) pathways in various neurodegenerative disorders, particularly Parkinson s disease, are also examined. This book sheds light on bioactive compounds from natural products that target kinases and explains the role of different kinases in various pathogenic pathways and mechanisms involved in neurodegeneration, including regulated cell death, autophagy, synaptic dysfunction, and neuroinflammation.

Portrait

Heba Mohamed Mansour, Ph.D. is currently the Manager of the Innovative Products' Technical Evaluation Unit at the Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-Inn) at the Egyptian Drug Authority (EDA). She is a topic leader in the ICH working group (EWG S13), specializing in non-clinical safety assessments of oligonucleotide-based therapeutics (ONTs). Heba received a PhD degree in pharmacology and toxicology from the Faculty of Pharmacy, Cairo University in 2024. She also received a diploma in environmental health from Ajloun University, Jordan. Her expertise encompasses a profound understanding of diverse cell death modalities in neurodegeneration and the exploration of potential drug repositioning strategies involving anti-cancer kinase inhibitors for neurodegenerative disorders. Her contributions extend to numerous research articles, prestigious international journal publications, book chapters, books, and comprehensive review articles, solidifying her interest in the field.

Scopus Author ID: 57222590031

Orchid ID: 0000-0001-7102-7305

Aiman Saad El-Khatib, Ph.D. is a Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University since May 2002. He is a former vice president of Egyptian Drug Authority (EDA). He held several leadership positions in Cairo University, including Vice President for Graduate Studies and Research Affairs, Dean of Faculty of Pharmacy, Vice Dean for Education and Students Affairs, as well as Vice Dean for Community Service and Environment Development. Additionally, he held the post of Assistant Minister of Health and Population for Pharmaceutical Affairs. His primary research area of interest is the?investigation of the pharmacological properties of various drugs, including natural products on the gastrointestinal tract, cardiovascular, and central nervous systems. He published numerous articles in international journals. His awards include Cairo University Scientific Research Fosterage in the?field of Theoretical and Applied Biological Sciences in 2004?and Silver and Gold Medal of Merit from the Egyptian Syndicate of Pharmacists in 2004 and 2005.

Scopus Author ID: 7003395602

Orchid ID: 0000-0002-2074-8337

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

28.05.2026

Herausgeber Heba Mohamed Mansour + weitere
Verlag Elsevier Science & Technology

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

28.05.2026

Herausgeber
Verlag Elsevier Science & Technology
Seitenzahl

592

Maße (L/B/H)

27,7/21,4/2,8 cm

Gewicht

1406 g

Sprache

Englisch

ISBN

978-0-443-44173-8

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Protein Serine/Threonine Kinases in Neurodegenerative Disorders
  • 1. Protein serine/threonine kinases: An overview
    2. Protein kinase C (PKC) in Neurodegenerative disorders
    3. AMP-activated protein kinase (AMPK) in neurodegenerative disorders
    4. Death-associated protein kinase 1 (DAPK1) in neurodegenerative disorders
    5. The mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases (Trk receptors for neurotrophin) and their roles in neurodegeneration
    6. Cyclin-dependent kinases (CDKs) in neurodegenerative disorders
    7. Unlocking the Potential of GSK-3ß Inhibitors in Neurodegenerative Disease Prognosis: Insights from Glucagon-like Peptide-1 Receptor Agonist Effects
    8. Rho-Associated Coiled-Coil-Containing Protein Kinase (ROCK) in neurodegenerative disorders
    9. Microtubule Affinity-Regulating Kinases (MARKs) in neurodegenerative disorders
    10. Mammalian target of Rapamycin (mTOR) in neurodegenerative disorders
    11. Leucine-Rich Repeat Kinase 2 (LRRK2): A Potential Target in Parkinson’s Disease and Beyond
    12. PTEN-induced kinase 1 (PINK1) in neurodegenerative disorders
    13. Dual-specificity Tyrosine phosphorylation-Regulated Kinase-1A (DYRK1A) in Neurodegenerative disorders
    14. AKT pathway as therapeutic target in neurodegenerative diseases: mechanisms and implications
    15. Targeting AKT pathways: A potential therapeutic target for Parkinson's disease
    16. Non-coding RNAs Regulating Serine/Threonine Kinases in Neurodegeneration
    17. Protein serine/threonine signaling pathways: Opportunities and translational perspectives
    18. Natural Products in Neurodegenerative Diseases: Role of Serine/Threonine Kinases
    19. Targeting autophagy-related serine/threonine kinases to combat neurodegenerative disorders
    20. Targeting regulated cell death-related serine/threonine kinases to combat neurodegenerative disorders
    21. Splicing Kinases in Neuronal Health and Neurodegeneration
    22. Balancing Efficacy and Safety: Protein Kinase Inhibitors and Drug-Induced Liver Injury
    23. Targeting serine/threonine kinases: Therapeutic innovations for neurodegenerative disorders